Cardiac Resynchronization Therapy Market to Reach USD 7.36 Billion by 2035 at 5.4% CAGR as Conduction-System Pacing Expands Eligible Heart Failure Population

The global cardiac resynchronization therapy market size was USD 4.35 Billion in 2025 and is expected to register a revenue CAGR of 5.4% during the forecast period. Cardiac resynchronization therapy treats heart failure in patients whose heart chambers contract out of synchrony, using a CRT-pacemaker or a CRT-defibrillator to coordinate the contraction of the lower chambers and improve pumping efficiency. These systems comprise implantable pulse generators, leads, and programmers.

Heart failure is a large and rising clinical burden, with the American Heart Association estimating that approximately 6.7 million adults in the United States are affected, and tens of millions more worldwide. Prevalence continues to increase as populations age, as hypertension and diabetes become more common, as well as from improved survival following heart attacks. Clinical practice guidelines establish cardiac resynchronization therapy as a standard treatment for eligible heart failure patients with reduced ejection fraction and electrical dyssynchrony, which anchors consistent referral volumes and reimbursement for the therapy across major markets.

The market entered the forecast period shaped by advances in device technology and expanding clinical applications. Longer battery life, magnetic-resonance-conditional designs, and remote monitoring capabilities improve the patient and clinician experience, while conduction-system pacing including left bundle branch area pacing offers a more physiological approach for selected heart failure patients.

Medtronic, whose Cardiac Rhythm and Heart Failure division includes resynchronization therapy devices, reported division revenue of USD 4.659 Billion for the nine months ended January 2025, reflecting sustained clinical demand. For instance, in the quarter ended October 2025, Medtronic plc, Ireland, which is the global leader in cardiac rhythm management, reported that its Cardiac Rhythm and Heart Failure division revenue reached USD 1.825 Billion, a mid-teens year-on-year increase, reflecting strong procedural demand for resynchronization and defibrillation devices in its key markets. These are some of the key factors driving revenue growth of the market.

However, cardiac resynchronization therapy remains underutilized despite clear guideline indications, with eligible patients including women and patients of color receiving devices at lower rates due to referral gaps, access barriers, and the specialist expertise required for implantation. Advances in battery technology extend device service life, reducing the frequency of replacement procedures that historically contribute a meaningful share of device revenue. The emergence of conduction-system pacing as an alternative to conventional biventricular pacing in some patient groups, alongside advances in heart failure drug therapy, introduces competition for conventional CRT systems. These factors substantially limit cardiac resynchronization therapy market growth over the forecast period.

Request Your Free Sample Report: https://www.emergenresearch.com/request-free-sample/1947

SEGMENT HIGHLIGHTS

Based on product, the global cardiac resynchronization therapy market is segmented into CRT-defibrillators and CRT-pacemakers. The CRT-defibrillators segment holds a significantly large revenue share in the market. CRT-defibrillators combine resynchronization pacing with the ability to detect and treat life-threatening arrhythmias, and they dominate revenue because many heart failure patients eligible for resynchronization also carry an indication for sudden cardiac death protection. The higher per-unit value of combined devices as well as clinical preference for comprehensive therapy in higher-risk patients make CRT-D the leading product category. The CRT-pacemakers segment is expected to register a rapid revenue growth rate in the global market over the forecast period, as conduction-system pacing approaches including left bundle branch area pacing expand the application of pacemaker-based resynchronization to additional heart failure patients who do not require defibrillation.

Based on component, the global cardiac resynchronization therapy market is segmented into implantable pulse generators, leads, and programmers and accessories. The implantable pulse generators segment holds a significantly large revenue share as the core, highest-value component of each resynchronization system, housing the battery, electronics, and therapy delivery algorithms. The generator accounts for the majority of device value in each implant procedure, establishing it as the dominant component category across the market. The leads segment is expected to register a rapid revenue growth rate in the global market over the forecast period, as conduction-system pacing drives demand for dedicated pacing leads and site-selective delivery systems, and as left bundle branch area pacing requires specialised leads that carry higher value than conventional transvenous left ventricular leads.

Request a Discount on This Report: https://www.emergenresearch.com/request-for-discount/1947

REGIONAL HIGHLIGHTS

Based on regional analysis, the cardiac resynchronization therapy market in North America accounted for largest revenue share in 2025. The United States is the dominant country market, supported by high heart failure prevalence estimated at approximately 6.7 million adults by the American Heart Association, advanced electrophysiology practice, favourable reimbursement for CRT-D and CRT-P procedures, as well as the presence of the three leading global manufacturers in Medtronic, Boston Scientific, and Abbott. Boston Scientific's Resonate CRT-defibrillator and Visionist CRT-pacemaker families, each carrying the HeartLogic heart failure diagnostic for early decompensation detection, are widely adopted across U.S. implanting centres. The U.S.-Iran conflict, which escalated through late February 2026 and continued into Q1 and Q2 2026, raised costs for electronic components and specialty materials used in implantable device manufacturing, increasing the cost base for producers and procurement costs for hospital systems across the region.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom are the primary markets, where established electrophysiology practice and universal healthcare systems support consistent access to resynchronization therapy for eligible heart failure patients. Biotronik SE & Co. KG, headquartered in Germany, is a key regional supplier with a broad portfolio of cardiac rhythm management devices, and its resynchronization systems are widely used across European centres. The escalation of the U.S.-Iran conflict through Q1 and Q2 2026 raised energy and logistics costs across the region, adding supply chain uncertainty that affected procurement budgets and delivery timelines for implantable cardiac devices.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. China, Japan, and India are the primary markets, where rising heart failure prevalence driven by ageing populations and increasing cardiovascular risk factors, expanding cardiac care infrastructure, and improving access to electrophysiology services support the fastest regional growth in demand for resynchronization devices. MicroPort Scientific Corporation, headquartered in China, is an established domestic supplier of cardiac rhythm management devices and is expanding its resynchronization portfolio to meet demand from Chinese and regional hospitals. Supply chain disruptions arising from the U.S.-Iran conflict and its spillover effects through Q1 and Q2 2026 introduced procurement delays for imported device components across the region, affecting delivery timelines for capital cardiac equipment.

Read the Full Report Description: https://www.emergenresearch.com/industry-report/cardiac-resynchronization-therapy-market

MAJOR COMPANIES IN THE REPORT INCLUDE:

Medtronic plc (Ireland)
Abbott Laboratories (United States)
Boston Scientific Corporation (United States)
Biotronik SE & Co. KG (Germany)
MicroPort Scientific Corporation (China)
LivaNova plc (United Kingdom)
Lepu Medical Technology Co., Ltd. (China)
Shree Pacetronix Ltd. (India)
Osypka AG (Germany)
Vitatron (Medtronic) (Netherlands)
Oscor Inc. (United States)
Cook Medical LLC (United States)
Pacetronix Ltd. (India)

Contact
Eric Lee
Corporate Sales Specialist, USA
Emergen Research | Web: www.emergenresearch.com
Direct Line: +12092086299
E-mail: sales@emergenresearch.com

About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend existing in the market.

This release was published on openPR.